


# Cancer and Autoimmunity

---

Yehuda Shoenfeld  
M. Eric Gershwin

Editors



Elsevier



# **CANCER AND AUTOIMMUNITY**

This Page Intentionally Left Blank

# CANCER AND AUTOIMMUNITY

Editors:

**Prof. Yehuda Shoenfeld, M.D.**

*Department of Medicine 'B'*

*Research Unit of Autoimmune Diseases*

*Sheba Medical Center, Tel-Hashomer*

*Sackler Faculty of Medicine, Tel-Aviv University*

*Israel*

**Prof. M. Eric Gershwin, M.D.**

*University of California*

*Division of Rheumatology/Allergy and Clinical Immunology*

*School of Medicine, Davis, CA.*

*U.S.A.*



**2000**

**ELSEVIER**

**Amsterdam – Lausanne – New York – Oxford – Shannon – Singapore – Tokyo**

ELSEVIER SCIENCE B.V.  
Sara Burgerhartstraat 25  
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

© 2000 Elsevier Science B.V. All rights reserved.

This work is protected under copyright by Elsevier Science, and the following terms and conditions apply to its use:

#### **Photocopying**

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: [permissions@elsevier.co.uk](mailto:permissions@elsevier.co.uk). You may also contact Rights & Permissions directly through Elsevier's home page (<http://www.elsevier.nl>), selecting first 'Customer Support', then 'General Information', then 'Permissions Query Form'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 171 436 5931; fax: (+44) 171 436 3986. Other countries may have a local reprographic rights agency for payments.

#### **Derivative Works**

Table of contents may be reproduced for internal circulation, but permission of Elsevier Science is required for external resale or distribution of such material.

Permission of the publisher is required for all other derivative works, including compilations and translations.

#### **Electronic Storage or Usage**

Permission of the publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter. Contact the publisher at the address indicated.

Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.

#### **Notice**

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

First edition 2000

Library of Congress Cataloging in Publication Data

A catalog record from the Library of Congress has been applied for.

ISBN 0-444-50331-5

⊗ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

Printed in The Netherlands.

## ***Dedication***

We dedicate this book to our wives:

Irit and Laurel

This Page Intentionally Left Blank

## PREFACE

To some people, the study of cancer and autoimmunity may be something only slightly less sterile than a Johnson & Johnson gauze pad, a pursuit followed by dilettanti and pseudo-scholastic professors. To others, the word connotes the exotic, the esoteric and the desirable. To us, it embodies the hopes and ambitions of generating an anti-tumor response in the patient.

It is somewhat ironic that over forty years ago there were two disciplines that started with “TI”. There was tumor immunology and there was transplantation immunology. The latter thrived and has led to some of the most critical discoveries in immunobiology. The former continues to thwart bench scientists and clinicians alike. In fact, the original hope that cancer cells would each contain a novel antigen that might be recognized by the immune system has proven, for the most part, to be naive. On the other hand, it was perhaps equally naive to assume that a process as biologically conserved as neoplasia, would lead to the production of something as simple as a unique antigen that would be common to all patients. The work, however, on tumor immunology has been productive and has led to interrelationships between the molecular processes of neoplastic development and the understanding of the phenotypic changes which occur. These changes which were once considered to be only involved in cell surface markers, now encompass the disciplines of signal transduction, apoptosis, and differentiation.

As immunologists, our goal is to develop a simple and effective means to manipulate cancer *in vivo*. This manipulation can encompass several venues. First, it might be as direct as the original hope and aspiration of identifying a phenotypic marker and the use of either active or passive immunization. Second, it might include the use of passive reagents carrying “warheads” to selectively destroy cancer cells. Third, it might include altering the basic process of cell survival, be it via nucleic acid or protein biosynthesis, or programmed cell death. The list goes on and on as the black box gets bigger and bigger. In fact, we used to teach our students that the immune system was little more than a large black box, except that upon opening the box, one only discovered multiple smaller black boxes, and so on. This volume is an attempt by a collection of workers in many disciplines, to present a theme which has not been well described before. The papers include both basic and clinical science and range from sophisticated molecular biology to little more than phenomenology (e.g., the increased association of cancer in some autoimmune diseases and increased presentation of autoimmune phenomena in malignant conditions). This, however, is state-of-the-art. Our hope is that this collection of themes will be of use not only to bench scientists, but also to clinicians who treat patients. We also expect that as we enter the millenium, that much of this work will become an anachronism. The latter of course would be a great success and would imply real progress. In fact, as we finish this volume, the editors realize more than anything else the need to update this book 5–10 years hence.

We greatly appreciate the help of our contributors. We have done our best to edit the manuscripts. The errors which remain are ours alone.

Y.S. and M.E.G.



This Page Intentionally Left Blank

## List of Contributors

### **Mahmud Abu-Shakra**

Rheumatic Diseases Unit and  
Department of Medicine 'B' & 'D'  
Soroka Medical Center and Ben-Gurion University  
P.O. Box 151  
Beer-Sheva 84101  
Israel

### **Donato Alarcon-Segovia**

Department of Immunology and Rheumatology  
Institute Nacional De La Nutricion  
Salvador Zubiran  
Mexico City  
Mexico

### **C. Alessandri**

University di Roma "La Sapienza"  
Policlinico Umberto I  
Clinica Medica I  
00161 Roma  
Italy

### **Anabel Aron-Maor**

Department of Medicine 'B'  
Research Unit of Autoimmune Diseases  
Chaim Sheba Medical Center  
(Affiliated to Tel-Aviv University)  
Tel-Hashomer 52621  
Israel

### **Ronald A. Asherson**

The Rheumatic Diseases Unit  
Department of Medicine  
University of Cape Town School of Medicine  
The Groote Schuur Hospital  
Observatory 7925  
Cape Town 8001  
South Africa

### **Antonio Bandeira**

Instituto Gulbenkian de Ciência  
Oeiras  
Portugal

### **Yaron Bar-Dayan**

INSERM Unité 430  
Hôpital Broussais  
96, Rue Didot  
75014 Paris Cedex 14  
France

### **Yosefa Bar-Dayan**

INSERM Unité 430  
Hôpital Broussais  
96, Rue Didot  
75014 Paris Cedex 14  
France

### **Eytan R. Barnea**

The S.I.E.P  
Division of Research  
Scientific Secretariat and Registration  
1697 Lark Lane, Cherry Hill  
New Jersey 08003-3157  
USA

### **Narayan K. Bhat**

Center for Molecular and Structural Biology  
Hollings Cancer Center  
Medical University of South Carolina  
17 Ashley Avenue  
Charleston, S.C. 29425-2213  
USA

**Emmanuelle Bonnin**

INSERM Unité 430  
Hôpital Broussais  
96, Rue Didot  
75014 Paris Cedex 14  
France

**Dan Buskila**

Rheumatic Disease Unit  
Department of Medicine 'B'  
Soroka Medical Center and Faculty of Health Science  
Ben-Gurion University of the Negev  
P.O. Box 151  
Beer-Sheva 84101  
Israel

**Mary C. Cantrell**

Division of Rheumatology/  
Allergy and Clinical Immunology  
University of California at Davis  
TB 192, School of Medicine  
Davis, CA 95616-8660  
USA

**Carlos A. Casiano**

Department of Microbiology and Molecular Genetics  
Loma Linda University School of Medicine  
Loma Linda, CA 922350  
USA

**Ricard Cervera**

Unitat de Malalties Autoimmunes Sistemiques  
Hospital Clinic, Villarroel 170  
Barcelona 08036  
Catalonia  
Spain

**Karsten Conrad**

Institute for Immunology  
Medical Faculty  
Technical University of Dresden  
Karl Marx Str. 3  
P.O. Box 8001 15  
D-01101 Dresden  
Germany

**Fabrizio Conti**

University di Roma "La Sapienza"  
Policlinico Umberto I  
Clinica Medica I  
00161 Roma  
Italy

**Antonio Coutinho**

Department of Immunology  
Pasteur Institute  
25 Rue du Docteur Roux  
75724 Paris Cedex 15  
France

**Sidney Croul**

Center for Neurovirology and Neurooncology  
MCP Hahnemann University  
245 N. 15th Street, Mail Stop #406  
Philadelphia, PA 19102  
USA

**David D'Cruz**

Bone & Joint Research Unit  
The Royal London Hospital  
25-29 Ashfield Street  
Whitechapel  
London E1 2AD  
England

**Jocelyne Demengeot**

Unité du Développement des Lymphocytes  
CNRS URA 1961  
Institut Pasteur  
Paris  
France

**Luis Del Valle**

Center for Neurovirology and Neurooncology  
MCP Hahnemann University  
245 N. 15th Street, Mail Stop #406  
Philadelphia, PA 19102  
USA

**Smruti A. Desai**

New York Medical College  
Department of Microbiology & Immunology  
Valhalla, New York 10505  
USA

**Guilliam Dighiero**

Institut Pasteur  
Unité d'Immuno-Hématologie et  
d'Immunopathologie  
28 rue du Dr Roux  
F-75724 Paris Cedex 15  
France

**Lea Eisenbech**

Department of Immunology  
Weizmann Institute of Science  
Rheovot 76100  
Israel

**Khaled M. El-Shami**

Department of Immunology  
Weizmann Institute of Science  
Rheovot 76100  
Israel

**Felix Fernández-Madrid**

Department of Internal Medicine  
Division of Rheumatology and  
Center for Molecular Medicine and Genetics  
Wayne State University  
4707 St. Antoine  
Detroit MI 48201  
USA

**Soldano Ferrone**

New York Medical College  
Department of Microbiology & Immunology  
Valhalla, New York 10505  
USA

**Claire Fieschi**

Médecin des Hopitaux  
Groupe Hospitalier  
Pitié—Salpêtrière  
47–83 Bd de l'Hôpital  
75651 Paris Cedex 13  
France

**Heiko T. Flammann**

Institute of Immunology  
Pathology and Molecular Biology  
Lademannbogen 61  
D-22339 Hamburg  
Germany

**Josep Font**

Unitat de Malalties Autoimmunes Sistèmiques  
Hospital Clinic, Villarroel 170  
Barcelona 08036  
Catalonia  
Spain

**Mario Garcia-Carrasco**

Unitat de Malalties Autoimmunes Sistèmiques  
Hospital Clinic, Villarroel 170  
Barcelona 08036  
Catalonia  
Spain

**Jacob George**

Department of Medicine 'B' and  
The Research Unit of Autoimmune Diseases  
Chaim-Sheba Medical Center  
Tel-Hashomer 52621  
Israel

**Panagiotis Georgiou**

Center for Molecular and Structural Biology  
Hollings Cancer Center  
Medical University of South Carolina  
17 Ashley Avenue  
Charleston, S.C. 29425-2213  
USA

**Eric M. Gershwin**

Division of Rheumatology/  
Allergy and Clinical Immunology  
University of California at Davis  
TB 192, School of Medicine  
Davis, CA 95616-8660  
USA

**Pascal Godmer**

Department of Internal Medicine  
Hôpital Avicenne  
Université Paris-Nord  
125, Rue de Stalingrad  
93000 Bobigny  
France

**Jennifer Gordon**

Center for Neurovirology and Neurooncology  
MCP Hahnemann University  
245 N. 15th Street, Mail Stop #406  
Philadelphia, PA 19102  
USA

**Wolfgang L. Gross**

University Poliklinik für Rheumatologie, Lubeck  
Ratzeburger Allee 160  
23538 Lubeck  
And Akad. Lehrkrankenhaus der Rheumaklinik B.B.  
Postfach 1488 Bramstedt 24572  
Germany

**Loïc Guillevin**

Department of Internal Medicine  
Hôpital Avicenne  
Université Paris-Nord  
125, Rue de Stalingrad  
93000 Bobigny  
France

**Michael Heike**

Johannes Gutenberg-Universität Mainz Klinikum  
I. Medizinische Klinik und Poliklinik  
Das Klinikum befindet sich in der  
Langenbeckstraße 1  
55131 Mainz  
Germany

**Shohei Hori**

Department of Immunology  
Pasteur Institute  
25 Rue du Docteur Roux  
75724 Paris Cedex 15  
France

**C. Jamin**

Centre Hospitalier Universitaire  
Laboratoire d'Immunologie  
B.P. 824  
F-29609 Brest Cedex  
France

**Viggo Jønsson**

Department of Autoimmunology  
Statens Serum Institut  
5 Artillerivej  
2300 Copenhagen 5  
Denmark

**Srinivas Kaveri**

INSERM Unité 430  
Hôpital Broussais  
96, Rue Didot  
75014 Paris Cedex 14  
France

**Michel D. Kazatchkine**

INSERM Unité 430  
Immunopathologie Humaine  
Hôpital Broussais  
96 Rue Didot  
75014 Paris Cedex 14  
France

**Kamel Khalili**

Center for Neurovirology and Neurooncology  
MCP Hahnemann University  
245 N. 15th Street, Mail Stop #406  
Philadelphia, PA 19102  
USA

**Arnoldo Kraus**

Department of Immunology and Rheumatology  
Instituto Nacional De La Nutricion  
Salvador Zubiran  
Mexico City  
Mexico

**Barbara Krynska**

Center for Neurovirology and Neurooncology  
MCP Hahnemann University  
245 N. 15th Street, Mail Stop #406  
Philadelphia, PA 19102  
USA

**Hella-Monika Kuhn**

Israelitic Hospital  
Orchideenstieg 14  
D-22297 Hamburg  
Germany

**Nitza Lahat**

Immunology Research Unit  
Carmel Medical Center  
7, Michal Str.  
Haifa 34362  
Israel

**Steven P. Levine**

The S.I.E.P  
Division of Research  
Scientific Secretariat and Registration  
1697 Lark Lane, Cherry Hill  
New Jersey 08003-3157  
USA

**Peter M. Lydyard**

Centre Hospitaluer Universitaire  
Laboratoire d'Immunologie  
B.P. 824  
F-29609 Brest Cedex  
France

**Ioanna Maroulakou**

Center for Molecular and Structural Biology  
Hollings Cancer Center  
Medical University of South Carolina  
17 Ashley Avenue  
Charleston, S.C. 29425-2213  
USA

**Karl-Herman Meyer zum Buschenfelde**

Office: I. Med. Klinik und Poliklinik  
Universität Mainz D55131  
Germany

**Ariel Miller**

Immunology Research Unit  
Carmel Medical Center  
7, Michal Str.  
Haifa 34362  
Israel

**Mathias Montenarh**

Universität des Saarlandes  
Medizinische Biochemie und Molekularbiologie  
Geb. 44  
66421 Hamburg  
Germany

**Arnon Nagler**

Department of Bone Marrow Transplantation  
Hadassah University Hospital  
Ein Karem  
Jerusalem 91120  
Israel

**Elvyra J. Noronha**

New York Medical College  
Department of Microbiology & Immunology  
Valhalla, New York 10505  
USA

**Jessica Otte**

Center for Neurovirology and Neurooncology  
MCP Hahnemann University  
245 N. 15th Street, Mail Stop #406  
Philadelphia, PA 19102  
USA

**Takis S. Papas**

Center for Molecular and Structural Biology  
Hollings Cancer Center  
Medical University of South Carolina  
17 Ashley Avenue  
Charleston, S.C. 29425-2213  
USA

**J.O. Pers**

Centre Hospitaluer Universitaire  
Laboratoire d'Immunologie  
B.P. 824  
F-29609 Brest Cedex  
France

**Jean-Charles Piette**

Medecin des Hopitaux  
Groupe Hospitalier  
Pitié—Salpêtière  
47–83 Bd de l'Hôpital  
75651 Paris Cedex 13  
France

**Miloslav Pospíšil**

Academy of Science of Czech Republic  
Prague  
Czech Republic

**Sonja Praprotnik**

University Medical Center Ljubiana  
Department of Rheumatology  
Vodnikova 62  
1000 Ljubiana  
Slovenia

**Nagenda Prasad**

INSERM Unité 430  
Hôpital Broussais  
96, Rue Didot  
75014 Paris Cedex 14  
France



**Roberta Priori**

University di Roma “La Sapienza”  
Policlinico Umberto I  
Clinica Medica I  
00161 Roma  
Italy

**Thomas P. Prindiville**

Division of Rheumatology/  
Allergy and Clinical Immunology  
University of California at Davis  
TB 192, School of Medicine  
Davis, CA 95616-8660  
USA

**O. Pritsch**

Institut Pasteur  
Unite d’Immuno-Hematologie et  
d’Immunopathologie  
28 rue du Dr Roux  
F-75724 Paris Cedex 15  
France

**Michal A. Rahat**

Immunology Research Unit  
Carmel Medical Center  
7, Michal Str.  
Haifa 34362  
Israel

**Manel Ramos-Casals**

Unitat de Malalties Autoimmunes Sistemiques  
Hospital Clinic, Villarroel 170  
Barcelona 08036  
Catalonia  
Spain

**Ernst Peter Rieber**

Institute of Immunology  
Medical Faculty  
Technical University of Dresden  
Karl-Marx-Str. 3  
D-01109 Dresden  
Germany

**Jozef Rovensky**

Research Institute of Rheumatic Diseases  
Nabrezie I. Krasku 4  
921 01 Piestany  
Slovak Rep.

**Marc Schmitz**

Institute of Immunology  
Medical Faculty  
Technical University of Dresden  
Karl-Marx-Str. 3  
D-01109 Dresden  
Germany

**Yaniv Sherer**

Department of Internal Medicine ‘B’  
Sheba Medical Center  
Tel Hashomer 52621  
Israel

**Yehuda Shoenfeld**

Department of Medicine ‘B’  
Research Unit of Autoimmune Diseases  
Chaim Sheba Medical Center  
(Affiliated to Tel-Aviv University)  
Tel-Hashomer 52621  
Israel

**Emanuel Sikuler**

Department of Medicine ‘B’  
Research Unit of Autoimmune Diseases  
Chaim Sheba Medical Center  
(Affiliated to Tel-Aviv University)  
Tel-Hashomer 52621  
Israel

**Shimon Slavin**

Department of Bone Marrow Transplantation  
Hadassah University Hospital  
Ein Karem  
Jerusalem 91120  
Israel

**Sooryanarayana**

INSERM U430  
Hospital Broussais  
Sheba Medical Center  
Tel Hashomer  
Israel

**Renata Štěpánková**

Academy of Science of Czech Republic  
Prague  
Czech Republic

**Efstratios Tatsis**

University Poliklinik für Rheumatologie, Lubeck  
Ratzeburger Allee 160  
23538 Lubeck  
And Akad. Lehrkrankenhaus der Rheumaklinik B.B.  
Postfach 1488 Bramstedt 24572  
Germany

**Moshe Tishler**

Department of Rheumatology  
Tel Aviv Souraski Medical Center  
Tel-Aviv University Sackler School of Medicine  
6 Weiman St.  
Tel Aviv 64239  
Israel

**Helena Tlaskalová**

Academy of Science of Czech Republic  
Prague  
Czech Republic

**Ludmila Tučková**

Academy of Science of Czech Republic  
Prague  
Czech Republic

**Yaron Tomer**

Department of Endocrinology  
Box 1055  
Mount Sinai Medical Center  
One Gustave L. Levy Place  
New York, N.Y. 10029  
USA

**J. Tomkiel**

Department of Internal Medicine  
Division of Rheumatology and  
Center for Molecular Medicine and Genetics  
Wayne State University  
4707 St. Antoine  
Detroit MI 48201  
USA

**M. Tomšič**

University Medical Center Ljubljana  
Department of Rheumatology  
Vodnikova 62  
1000 Ljubljana  
Slovenia

**Alena Tuchyňová**

Research Institute of Rheumatic Diseases  
Nabrezie I. Krasku 4  
921 01 Piestany  
Slovak Rep.

**Guido Valesini**

University di Roma "La Sapienza"  
Policlinico Umberto I  
Clinica Medica I  
00161 Roma  
Italy

**F. Viganego**

University di Roma "La Sapienza"  
Policlinico Umberto I  
Clinica Medica I  
00161 Roma  
Italy

**Antonio R. Villa**

Department of Immunology and Rheumatology  
Institute Nacional De La Nutricion  
Salvador Zubiran  
Mexico City  
Mexico

**Xinhui Wang**

New York Medical College  
Department of Microbiology & Immunology  
Valhalla, New York 10505  
USA

**Dennis K. Watson**

Center for Molecular and Structural Biology  
Hollings Cancer Center  
Medical University of South Carolina  
17 Ashley Avenue  
Charleston, S.C. 29425-2213  
USA

**Allan Wiik**

Department of Autoimmunology  
Statens Serum Institut  
5 Artillerivej  
2300 Copenhagen 5  
Denmark

**Joerg Willers**

New York Medical College  
Department of Microbiology & Immunology  
Valhalla, New York 10505  
USA

**Dongsheng Zhang**

New York Medical College  
Department of Microbiology & Immunology  
Valhalla, New York 10505  
USA

**Pierre Youinou**

Centre Hospitaluer Universitaire  
Laboratoire d'Immunologie  
B.P. 824  
F-29609 Brest Cedex  
France

# CONTENTS

Preface	vii
List of Contributors	ix
Introduction: The Immune System, the Autoimmune State and Autoimmune Disease <i>Jacob George and Yehuda Shoenfeld</i>	1
<b>I Malignancies in Autoimmune Diseases</b>	
Rheumatoid Arthritis and Cancer <i>Mahmoud Abu-Shakra, Dan Buskila and Yehuda Shoenfeld</i>	19
SLE and Cancer <i>Mahmoud Abu-Shakra, Dan Buskila and Yehuda Shoenfeld</i>	31
Malignancies Occurring in Scleroderma <i>Pascal Godmer and Loïc Guillevin</i>	41
PSS (Scleroderma) and Cancer <i>Anabel Aron-Maor and Yehuda Shoenfeld</i>	45
Vasculitis and Malignancy <i>Efstathios Tatsis and Wolfgang L. Gross</i>	49
Sjögren's Syndrome and Lymphoproliferative Disease <i>Manel Ramos-Casals, Mario García-Carrasco, Josep Font and Ricard Cervera</i>	55
Polymyalgia Rheumatica, Temporal Arteritis and Occurrence of Malignant Tumors <i>Jozef Rovenský and Alena Tuchyňová</i>	81
Myositis and Neoplasia <i>Claire Fieschi and Jean-Charles Piette</i>	85
Antiphospholipid Antibodies and Malignancies <i>Ronald A. Asherson and R. Cervera</i>	93
Malignancy in Coeliac Disease and Dermatitis Herpetiformis <i>Helena Tlaskalová, Ludmila Tučková, Miloslav Pospíšil and Renata Štěpánková</i>	105
Autoimmune Rheumatic Diseases and Cancer: Evidence of Causality? <i>Antonio R. Villa, Arnoldo Kraus and Donato Alarcón-Segovia</i>	111
<b>II Autoimmunity in Malignant States</b>	
Paraneoplastic Syndromes <i>Moshe Tishler and Yehuda Shoenfeld</i>	121
Paraneoplastic Arthritis <i>S. Praprotnik and M. Tomšič</i>	133
Autoantibodies, Autoimmunity and Cancer <i>Yaron Tomer and Yehuda Shoenfeld</i>	141
Antinuclear Antibodies as Potential Markers of Lung Cancer <i>F. Fernández-Madrid and J. Tomkiel</i>	151

Autoantibodies in Cancer Patients and in Persons with a Higher Risk of Cancer Development <i>Karsten Conrad</i>	159
Autoantibodies to the Proliferation-Associated Nuclear Protein CENP-F in Cancer <i>Carlos A. Casiano</i>	175
p53 Autoantibodies and Cancer: Specificity, Diagnosis and Monitoring <i>H.T. Flammann and H.-M. Kuhn</i>	181
Humoral Immune Response Against the Growth Suppressor p53 in Human Malignancies <i>Mathias Montenarh</i>	193
Expression of ETS Family of Genes in Systemic Lupus Erythematosus <i>Panagiotis Georgiou, Ioanna Maroulakou, Narayan K. Bhat, Dennis K. Watson and Takis S. Papas</i>	205
Immune Response to Tumor Stress Proteins—Implications for Vaccine Development Against Cancer <i>Michael Heike and Karl-Hermann Meyer zum Büschenfelde</i>	213
Autoimmunity and B-Cell Malignancies <i>O. Pritsch and G. Dighiero</i>	223
Autoimmunity in B-Lymphoproliferative Disorders <i>Viggo Jønsson and Allan Wiik</i>	233
CD5 Positive B Cells: Crossroads of Autoimmunity and Lymphoid Malignancy <i>C. Jamin, J.O. Pers, P.M. Lydyard and P. Youinou</i>	241
Thymoma and Autoimmune Diseases <i>Yaniv Sherer and Yehuda Shoenfeld</i>	249
Castleman's Disease and Autoimmunity <i>C. Alessandri, F. Viganego and G. Valesini</i>	253
<b>III Mechanisms in Cancer and Autoimmunity</b>	
IgA and Cancer <i>Thomas P. Prindiville, Mary C. Cantrell, Yehuda Shoenfeld and M. Eric Gershwin</i>	261
Apoptosis: The Relation Between Anti-Fas Antibodies, and Immunosurveillance Against Cancer and Autoimmunity <i>Yaron Bar-Dayana, Sooryanarayana, Emmanuelle Bonnin, Nagendra Prasad, Yosefa Bar-Dayana, Michel D. Kazatchkine and Srinivas V. Kaveri</i>	277
Hepatitis C Virus, Autoimmunity and Cancer <i>Dan Buskila, Emanuel Sikuler and Yehuda Shoenfeld</i>	285
The Human Neurotropic Virus, JCV, and Its Association with CNS Tumors <i>Kamel Khalili, Luis Del Valle, Barbara Krynska, Jennifer Gordon, Jessica Otte and Sidney Croul</i>	297
The Smoking Cancer—Autoimmunity Connection <i>Jacob George and Yehuda Shoenfeld</i>	309
Significance and Regulation of the Expression of MHC Class II Molecules on Autoimmune and Neoplastic Thyroid Cells <i>Nitza Lahat, Ariel Miller and Michal A. Rahat</i>	317
Cancer Immunity: A Problem of Self-Tolerance <i>Shohei Hori, Jocelyne Demengeot, Antonio Bandeira and Antonio Coutinho</i>	337
Maternal Immune Response to Trophoblast, GTD, and Cancer <i>Eytan R. Barnea and Steven P. Levine</i>	343
<b>IV Therapy in Autoimmunity and Cancer—Common and Different Denominators</b>	
Therapy of Cancer and Autoimmunity: Immuno-modulatory Strategies Based on Modified Dendritic Cells <i>Marc Schmitz and Ernst Peter Rieber</i>	353

Anti-Idiotypic Therapy in Autoimmunity	365
<i>Dan Buskila, Mahmoud Abu-Shakra and Yehuda Shoenfeld</i>	
Active Specific Immunotherapy of Malignant Diseases—Breaking Tolerance to Self-Antigens with Tumor Associated Antigen Mimics	379
<i>Elyvra J. Noronha, Xinhui Wang, Smruti A. Desai, Dongsheng Zhang, Joerg Willers and Soldano Ferrone</i>	
Antigen-Specific Antitumor Vaccination: Immunotherapy Versus Autoimmunity	397
<i>Lee Eisenbach and Khaled M. El-Shami</i>	
Bone Marrow Transplantation for Cancer and Autoimmunity	409
<i>Shimon Slavin and Arnon Nagler</i>	
Postchemotherapy Rheumatism	423
<i>David D’Cruz</i>	
Cyclosporin and Cancer	429
<i>Roberta Priori, Fabrizio Conti and Guido Valesini</i>	
Subject Index	437



This Page Intentionally Left Blank

# Introduction: The Immune System, the Autoimmune State and Autoimmune Disease

Jacob George and Yehuda Shoenfeld

*Department of Medicine 'B' and the Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

## 1. INTRODUCTION

Autoimmune diseases stand as important causes of morbidity and mortality in western society and as such, they impose a heavy burden in financial terms. The significance of autoimmune diseases can be demonstrated by the study showing that half of the patients with RA are unemployed due to medical disabilities resulting from their illness [1]. Similarly, patients with insulin dependent diabetes mellitus, an additional autoimmune disease, who today have a longer life expectancy, increasingly require supporting medical facilities such as dialysis.

The pathogenesis and the relative importance of factors leading to autoimmunity are not defined precisely. Key questions include: what is the origin of autoantibodies, thought to play a detrimental role in autoimmunity, their interrelations with the autoantigens to which they are directed and the influence of this interplay on the immune system. The enigma is further intensified by the detection of natural autoantibodies found in healthy organisms and thought to possess regulatory and protective properties. Moreover, the cellular immune response has similarly been shown to participate in the evolvement of autoimmunity through its principal effector—the T-cell. However, the initiating events rendering these cells autoreactive and therefore capable of precipitating damage to cell-structures and the precise nature of this reaction still await comprehensive elucidation.

## 2. THE ESSENTIALS OF THE IMMUNE RESPONSE

The principal role of the immune system is to confer protection on the organism against foreign invading pathogens, which can gain access to the body by different routes. The targeted (specific) immune response is generated by the combined interaction of the cellular and humoral responses, both coordinated by the production of active substances—the *cytokines*. Cellular immunity refers to the immune mechanisms mediated by T lymphocytes, regardless of immunoglobulin molecules, whereas humoral immunity denotes secretion of antibodies by B lymphocytes. The humoral and cellular arms of the immune system should be viewed, not as two independent mechanisms of self defense, but rather as acting in an orchestrated and synergistic manner to accomplish protection [2].

### 2.1. Humoral Immune Response

B-cells stem from bone marrow precursors and later localize in the circulation as well as in follicles of peripheral lymphoid tissues. They are responsible for the production of antibodies, once they have differentiated into plasma cells [3]. B-lymphocytes are also involved in antigen presentation to T-cells, secretion of immunoregulating cytokines and establishment of 'memory' towards antigenic determinants [4].

Direct activation of B-cells by distinct antigens is facilitated by binding to antigen receptors located within the membrane of the B-lymphocytes and under the influence of cytokines. This complex interac-

tion activates B-cells after which they proliferate and produce the appropriate antibody.

The final function of the B-cell (i.e., memory cell, plasma cell or cytokine secreting cell) is determined by the profile of the cytokines present, and the mechanisms of activation (through B-cell receptors for the Fc region of IgG, or for complement components) [4]. The end product following antigenic stimulation is a population of B-cells producing and secreting one specific antibody against the introduced antigen.

Immunoglobulins are glycoproteins forming 9 classes of isotypes: IgG, divided to 4 subclasses (IgG1-4), IgM, IgA comprising 2 subclasses (IgA1-2), IgD and IgE (Tables 1) [5]. The basic structure of immunoglobulins (similar in all five isotypes) consists of two identical heavy chains (MW 50,000–75,000) combined with two identical light chains (MW 25,000). Antigen specificity is determined by variable areas containing the antigen binding site, whereas the constant region (as can be inferred from its name), is common to all immunoglobulins of a certain class. The hypervariable region is located in the variable region, representing the closest relationship to the epitope (its corresponding site on the antigen). The idiotypes, located in the variable region are the antigenic determinants (defining antigen binding) of the immunoglobulins themselves.

The diversity of antibody response is formulated due to encoding of the heavy and light chains by multiple genetic elements. As such, light chains are generated following pairing of VK and JK genes, whereas heavy chains exhibit greater diversity since they are created following the assembly of three germline genes (VH, DH, JH).

## 2.2. Cellular Immune Response

A T-cell cycle is initiated in hematopoietic stem cells, differentiating in the thymus and subsequently wandering to the lymphoid tissue in the periphery [2, 6]. T-cells are heterogeneous by virtue of their different functions (lysis of foreign cells, modulation of the interaction between B and T cells, regulation of monocyte functions). The peripheral T-cells are discerned by their expression of antigenic markers. As such, T-cells carrying CD4 molecules (T-helpers) interact with antigen associated with MHC class II on the surface of the antigen presenting cell, and T-cells expressing

CD8 molecules (cytotoxic T-cells) engage in suppression of the immune response. The T-cell receptor is a molecule present on the surface of the T-cell, responsible for recognition of the complex antigen-MHC II molecule [7]. The variety of T-cell receptors is immense, thus accounting for its ability to recognize diverse antigens.

The immune response is mounted following presentation of the antigen to the lymphocytes by antigen presenting cells, examples of which are: macrophages, Langerhans cells and dendritic cells. The process of presentation requires the participation of MHC class II molecules on the surface of the antigen presenting cell. The antigen, prior to its presentation to the T-cell is processed and degraded and later associated with the MHC class II molecule to form a complex reacting with the T-cell receptor. It should be outlined that the APCs are capable of secreting cytokines that act to facilitate the interaction described above.

## 2.3. Coordination of the Immune Response

Several intrinsic factors belonging to the immune system itself are responsible for the modulation and regulation of the immune response.

*Cytokines* are small proteins (MW 8000-30,000) produced and secreted by a diverse population of cells (i.e., macrophages, monocytes, T and B cells, as well as nonlymphoid cells) [8]. Cytokines elicit different actions (Table 2) including proinflammatory (TNF, IL-1, IL-2) and anti-inflammatory (TGF, IL-4, IL-6, IL-10) functions and stimulation of lymphocyte proliferation (IL-2, IL-7).

The regulation of cytokines is under the supervision of genetic factors (capable of generating corresponding inhibitors) and by the liberation of soluble forms of cytokine receptors.

*The complement system* consists of circulating glycoprotein constituents that can be triggered and activated in two major patterns to initiate a cascading chain of events, the consequence of which leads to diverse influences on the progression and perpetuation of the immune response [9]. This cascade can, therefore, be activated by the *classical* pathway (immune complexes comprising IgM and IgG) or by the *alternative* pathway—independent of antibodies (by bacterial LPS).

*The idiotypic system*—will later be reviewed in detail.

**Table 1.** Characteristics of human immunoglobulin subclasses

Characteristic	IgG	IgM	IgA	IgD	IgE
Molecular form	Monomer	Pentamer, hexamer	Monomer, dimer	Monomer	Monomer
Molecular weight	160,000	900,000	170,000	180,000	190,000
Subclasses	1, 2, 3, 4	None	1, 2	None	None
Serum half life(days)	23	5.1	5.8	2.8	2.3
Valence	2	10, 12	2, 4	2	2
Serum concentration (mg/dl)	1000–1500	100–150	250–300	0.3–30	0.0015–0.2
Sedimentation constant	7S	19S	7S (9, 11, 13)	7S	8S
Percentage of serum immunoglobulins	75–85	5–10	7–15	0.3	0.0003
Placental transfer	+	–	–	–	–

**Table 2.** Representative cytokines and their corresponding biological activities

Cytokine	Activities
IL- $\alpha$ , IL- $\beta$	Lymphocyte activation; bone resorption, induction of fibroblasts synovial cells and endothelial cells; prostaglandin liberation.
IL-2	T and B growth factor; increased secretion of several cytokines; activation of cytotoxic cells.
IL-3	Proliferation of marrow stem cells; growth factor for: macrophages, eosinophils, mast cells.
IL-4	Activation of B-cells and macrophages; stimulated proliferation of T-cells and mast cells; Induce secretion of IgE by B-cells.
IL-6	Induce antibody production and acute phase protein production by the hepatocytes.
IL-10	Inhibit production of several cytokines
IFN- $\alpha$	Decrease cell replication; Increases MHC class I replication; disrupts viral replication.
IFN- $\gamma$	Activate NK cells, cytotoxic T cells, endothelial cells and macrophages; anti-tumoral effects; Increase expression of MHC class I and II.
TNF- $\alpha$	Acute phase reactant; anti-tumoral; activate macrophages; increase expression of MHC class I; bone resorption.
TGF- $\beta$	Inhibit IL-1; enhance tissue repair; suppress lymphocyte proliferation.

*Suppressor T-cells.* As can be recalled, suppressor T-cells constitute a distinct subset of T-cells in charge of down-regulating the expression of either T cells and immunoglobulin secreting cells [10].

### 3. EVOLUTION OF THE AUTOIMMUNITY CONCEPT

*Paul Ehrlich* was the first to coin the term *autoimmunity* [11] with regard to the harmful aspects of immunity, namely—the emergence of autoantibodies directed against the organism's own antigens. However, the expression used ('horror autotoxicus') has served to denote a mechanism avoiding autoimmunization, exemplified in goat models (producing alloantibodies but not autoantibodies).

The revolutionary ideas expressed by *Ehrlich* were subsequently abandoned for a century although anecdotal works confirming his notions were sporadically reported. The turning point, leading to the general acceptance of the autoimmunity concept was the experiments by *Witebski & Rose* (reviewed in Reference [12]) showing that rabbits immunized with rabbit thyroglobulin developed thyroiditis following production of anti-thyroglobulin autoantibodies. These observations were supported by the models of autoimmune hemolytic anemia and thrombocytopenia in which anti-red blood cell antibodies were detected and had been shown to be associated with bouts of hemolysis and thrombocytopenia [13].

The discovery of the NZB mouse (a strain which develops spontaneous autoimmune disease) provided a new tool for the study of autoimmunity, con-